<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01595321</url>
  </required_header>
  <id_info>
    <org_study_id>J1179</org_study_id>
    <secondary_id>NA_00050233</secondary_id>
    <nct_id>NCT01595321</nct_id>
  </id_info>
  <brief_title>Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas</brief_title>
  <official_title>Pilot Study Evaluating An Allogeneic GM-CSF-Transduced Pancreatic Tumor Cell Vaccine (GVAX) and Low Dose Cyclophosphamide Integrated With Fractionated Stereotactic Body Radiation Therapy (SBRT) and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate safety of a whole cell vaccine with immune
      modulating doses of cyclophosphamide followed by SBRT and FOLFIRINOX chemotherapy in
      pancreatic cancer patients after surgery.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of toxicity</measure>
    <time_frame>4 years</time_frame>
    <description>To determine the safety profile of the whole cell vaccine (GVAX) administered along with cyclophosphamide; fractionated SBRT, and FOLFIRINOX.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>4 years</time_frame>
    <description>To estimate the median overall survival (OS), disease-free survival (DFS), and distant metastases free survival (DMFS) using Kaplan-Meier techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression using immune correlates</measure>
    <time_frame>4 years</time_frame>
    <description>Correlate progression with the immune response through vaccine-induced changes in the number, function, avidity, size and diversity of the mesothelin-specific T cell repertoire).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>SBRT and FOLFIRINOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first 6 patients will receive SBRT and FOLFIRINOX only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclophosphamide, Vaccine, SBRT, and FOLFIRINOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The last 12 patients will receive cyclophosphamide, Vaccine, SBRT, and FOLFIRINOX.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional Cy-vaccine boosts may be given every 6 months thereafter until disease recurrence.</description>
    <arm_group_label>Cyclophosphamide, Vaccine, SBRT, and FOLFIRINOX</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine</intervention_name>
    <description>Vaccine will be administered one day after cyclophosphamide (day 1). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional Cy-vaccine boosts may be given every 6 months thereafter until disease recurrence.</description>
    <arm_group_label>Cyclophosphamide, Vaccine, SBRT, and FOLFIRINOX</arm_group_label>
    <other_name>Pancreatic cancer vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation (SBRT)</intervention_name>
    <description>SBRT (6.6 Gy) will be administered over 5 days starting between 13-17 days after the first vaccine dose (Arm 2) or within 6-10 weeks of surgery (Arm 1).</description>
    <arm_group_label>SBRT and FOLFIRINOX</arm_group_label>
    <arm_group_label>Cyclophosphamide, Vaccine, SBRT, and FOLFIRINOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRINOX</intervention_name>
    <description>FOLFIRINOX will be administered over 6 cycles starting at least 14 days after SBRT (Arms 1 and 2) and at least 28 days after the first vaccine (Arm 2).</description>
    <arm_group_label>SBRT and FOLFIRINOX</arm_group_label>
    <arm_group_label>Cyclophosphamide, Vaccine, SBRT, and FOLFIRINOX</arm_group_label>
    <other_name>Oxaliplatin</other_name>
    <other_name>Irinotecan</other_name>
    <other_name>Leucovorin</other_name>
    <other_name>Fluorouracil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (abbreviated):

          1. Documented cancer of the pancreas (head, neck, and/or uncinate process), that has been
             completely resected

          2. No prior Chemotherapy, radiation therapy or biologic therapy for pancreatic cancer

          3. Must be within 10 weeks from surgical resection of cancer

          4. Titanium clips (minimum 1) must be placed at the time of surgery to aid in SBRT
             treatment planning

          5. ECOG Performance Status of 0 to 1

          6. Adequate organ function as defined by study-specified laboratory tests

          7. Must use acceptable form of birth control through the study and for 28 days after
             final dose of study drug

          8. Signed informed consent form

          9. Willing and able to comply with study procedures

        Exclusion criteria (abbreviated):

          1. Currently have or have history of certain study-specified heart, liver, kidney, lung,
             neurological, immune or other medical conditions

          2. Presence of metastatic disease

          3. Clinical metabolic or laboratory abnormalities defined as Grade 3 or 4 of the National
             Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events (CTCAE),
             version 3.0

          4. Systemically active steroids

          5. Chemotherapy, radiation therapy or biologic therapy within 28 days prior to receiving
             study drug

          6. Inability to begin protocol treatment within 70 days (10 weeks) after surgery to
             remove cancer

          7. History of HIV, hepatitis B or C infection

          8. Pregnant or lactating

          9. Conditions, including alcohol or drug dependence, or intercurrent illness that would
             affect the patient's ability to comply with study visits and procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Laheru, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2012</study_first_submitted>
  <study_first_submitted_qc>May 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2012</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adjuvant therapy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Cytoxan</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Pancreatic Vaccine</keyword>
  <keyword>Stereotactic radiation therapy</keyword>
  <keyword>SBRT</keyword>
  <keyword>FOLFIRINOX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

